Celularity Inc

Insightful analysis of Celularity insider activity shows strategic use of convertible notes and warrants to hedge upside while awaiting 2026 clinical milestones, highlighting potential value unlock.

Celularity insider buys signal confidence in placenta‑derived NK and CAR‑T therapies; investors eye clinical milestones, regulatory paths, and value‑based reimbursement prospects.